This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
10x Genomics (TXG) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for 10x Genomics (TXG) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Outset Medical, Inc. (OM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Outset Medical, Inc. (OM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Axonics Modulation Technologies (AXNX) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Axonics (AXNX) delivered earnings and revenue surprises of 260% and 2.41%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
iRhythm Technologies (IRTC) Moves 7.4% Higher: Will This Strength Last?
by Zacks Equity Research
iRhythm Technologies (IRTC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
10x Genomics (TXG) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for 10x Genomics (TXG) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
10x Genomics (TXG) delivered earnings and revenue surprises of -35.90% and 5.65%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
10x Genomics (TXG) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
10x Genomics (TXG) delivered earnings and revenue surprises of -15.79% and 4.22%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
NextGen (NXGN) Riding on the Success of Cloud-Based Solution
by Zacks Equity Research
NextGen's (NXGN) cloud-based healthcare technology solutions boost the company's prospect. Strong adoption of its services continues to boost revenues.
10x Genomics (TXG) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
10x Genomics (TXG) delivered earnings and revenue surprises of 48.28% and 6.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Syneos Health (SYNH) Q4 Earnings Expected to Decline
by Zacks Equity Research
Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
10x Genomics (TXG) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Medical Info Systems Stocks Braving Industry-wide Headwinds
by Urmimala Biswas
Zacks Medical Info Systems industry stocks like 10x Genomics (TXG), NextGen Healthcare (NXGN) and Health Catalyst (HCAT) are expected to gain as COVID-19 severity fades.
10x Genomics (TXG) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
10x Genomics (TXG) delivered earnings and revenue surprises of 17.78% and 1.32%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Can Rising Visits Help Teladoc (TDOC) Beat on Earnings in Q3?
by Zacks Equity Research
The third-quarter results of Teladoc (TDOC) are likely to reflect a rise in Access Fees and Visit Fee revenues.
PacBio's (PACB) Latest Offering to Enhance Disease Discoveries
by Zacks Equity Research
PacBio's (PACB) latest sequencing kit is expected to help generate insights into how single-cell research can power new disease discoveries and the identification of therapeutic targets across many categories.
Inspire (INSP) Stock Jumps 5.6%: Will It Continue to Soar?
by Zacks Equity Research
Inspire (INSP) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
10x Genomics (TXG) delivered earnings and revenue surprises of -42.50% and 0.10%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
American Well Corporation (AMWL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
American Well Corporation (AMWL) delivered earnings and revenue surprises of 0% and 3.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Azenta (AZTA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Brooks (AZTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate 10x Genomics (TXG) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Gene Sequencing Stocks With Potential to Gain in 2H22
by Indrajit Bandyopadhyay
Here we look at three stocks, PKI, TMO and TXG, with robust genome sequencing capabilities that investors can keep a watch on.
10x Genomics (TXG) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
10x Genomics (TXG) delivered earnings and revenue surprises of -2.70% and 1.21%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
10x Genomics (TXG) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Illumina (ILMN) Invests in Seven Additional Genomics Startups
by Zacks Equity Research
Illumina's (ILMN) investment in seven new genomics companies is intended to advance breakthrough therapeutics, diagnostics, DNA storage, mental wellness and sustainable foods applications.
10x Genomics (TXG) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
10x Genomics (TXG) delivered earnings and revenue surprises of -166.67% and 2.83%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?